 Home > Active Ingredient News > Antitumor Therapy > Inovio announces the first phase III clinical success of innovative DNA immunotherapy treatment for cervical cancer

Inovio announces the first phase III clinical success of innovative DNA immunotherapy treatment for cervical cancer

 Last Update: 2021-03-19
 Source: Internet
 Author: User

Tags

human pheromones

human urine fertilizer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Inovio announced the positive results of the first phase III clinical trial of VGX-3100 for cervical precancerous lesions.

This is the fastest DNA therapy clinical trial in the world.

This project is jointly developed by INOVIO and China's innovative oncology pharmaceutical company Dongfanglue.

Infection prevention

HPV stands for Human Papillomavirus, and it is one of the most common viruses that cause infectious diseases.

INOVIO announcements, the REVEAL the phase III trial 1 (pivotal Phase III trial) and REVEAL2 (phase III confirmatory test) in progress, is intended to evaluate and verify the safety VGX-3100, tolerability, immune immunogenic And effectiveness.

immunity

Dr.

Patients with vulvar cancer and anal cancer will also benefit

Compared with the well-known cervical precancerous lesions, anal precancerous lesions and vulvar precancerous lesions are two other diseases caused by HPV infection, and they are more difficult to treat.

INOVIO announced in early January this year: For the precancerous lesions of the vulva caused by HPV infection, the Phase II clinical trial showed good clinical effectiveness, safety and tolerability.

VGX-3100, as a key R&D project of Oriental Strategy and INOVIO in the field of DNA immunotherapy, once approved, it will be the first in the world to be developed for the treatment of HPV-related precancerous lesions (cervical precancerous lesions, anal precancerous lesions, vulvar precancerous lesions).

Develop biomarkers to improve effectiveness

Dr.

diagnosis

INOVIO announced in February this year that it will continue to cooperate with QIAGEN to develop an in vitro diagnostic product based on RNA sequencing technology in order to more effectively identify the patient population that responds to VGX-3100.

INOVIO stated that it will continue to follow up on REVEAL1 subjects for safety and durable response rates for 18 months after the last dose.

Dongfang Lue focuses on the clinical development and commercialization of innovative oncology drugs, and provides solutions to meet clinical needs.

About VGX-3100

VGX-3100 is the world's first therapeutic drug for HPV 16/18 infection-related precancerous lesions.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.